Trifluridine and Tipiracil Tablets (TrifluridineTipiracil) is a new type of oral antineoplastic drug, composed of trifluridine (a nucleoside metabolism inhibitor) and tipiracil (a thymidine phosphorylase inhibitor). It inhibits tumor cell proliferation through a dual-mechanism approach. Since its first approval in the United States in 2015, it has become an important treatment option for advanced colorectal cancer and gastric cancer.
Indications of Trifluridine and Tipiracil Tablets (TrifluridineTipiracil)
Treatment of Metastatic Colorectal Cancer
Monotherapy: Indicated for adult patients with metastatic colorectal cancer who have previously received chemotherapy based on fluoropyrimidines, oxaliplatin, and irinotecan, anti-VEGF biological therapy, and (for patients with wild-type RAS) anti-EGFR therapy.
Combination Therapy: Used in combination with bevacizumab for subsequent treatment of the same patient population mentioned above.
Treatment of Metastatic Gastric Cancer
Monotherapy: Indicated for adult patients with metastatic adenocarcinoma of the stomach or gastroesophageal junction who have previously received at least two chemotherapy regimens (including fluoropyrimidines, platinum agents, taxanes, or irinotecan) and, if applicable, have also received HER2/neu-targeted therapy.
Specifications and Properties of Trifluridine and Tipiracil Tablets (TrifluridineTipiracil)
15mg/6.14mg Tablet
Appearance Characteristics: White, biconvex, round film-coated tablet.
Marking System: Engraved with "15" on one side, and marked with "102" and "15mg" on the other side, all printed with gray ink.
20mg/8.19mg Tablet
Appearance Characteristics: Light red, biconvex, round film-coated tablet.
Marking System: Engraved with "20" on one side, and marked with "102" and "20mg" on the other side, all printed with gray ink.
Storage Conditions and Usage Specifications of Trifluridine and Tipiracil Tablets (TrifluridineTipiracil)
Core Storage Parameters
Temperature Control: Store at 20°C to 25°C (68°F to 77°F); short-term storage between 15°C and 30°C (59°F and 86°F) is permitted.
Usage Management Specifications
Administration Method: Swallow the tablet whole, take it with meals, twice a day.
Treatment Cycle: Administer on Days 1-5 and Days 8-12 of each 28-day cycle.
Special Precautions
If removed from the original bottle, the tablets must be used within 30 days.
Wear gloves when handling the drug, and wash hands promptly after contact.
Management of Abnormal Situations: Do not make up for a missed dose or a dose that was vomited; continue with the next scheduled dose as planned.
